Swiss Multinationals versus the French Welfare State? The Social Security Deficit, European Integration, and the Battle for 'Fair' Drug Prices (1970-1990) (original) (raw)
2024, Contemporary European History
Drawing on corporate and business association archives, this contribution investigates how Swiss multinational enterprises from the pharmaceutical industry (Ciba, Geigy, Hoffmann-La Roche, Sandoz) navigated governments’ interventions in France to preserve their profitability. Our analysis shows how diplomatic talks were crucial for Swiss firms having to cope with rising inflation and the freezing of drug prices, as well as increased customs controls targeting multinationals’ transfer prices. In particular, promises of future R&D were used as a tool in negotiations, and secrecy about prices and profits formation was key in maintaining pressure on the French government. The article also highlights that from the mid-1980s onwards, pharmaceutical multinationals promoted the creation of the Single Market, since it had the potential to enforce supranational rulings over national discretionary pricing policies.
Related papers
The Swiss pharmaceutical industry
The Swiss pharmaceutical industry. The impact of industrial property rights an trust in the laboratory, 1907-1939, in: A.S. Travis et al. (eds.), Determinants in the Evolution of the European Chemical Industry, 1900-1939. Netherlands 1998, S. 257-271., 1998
THE POLITICAL ECONOMY OF HEALTH IN FRENCH TERRITORY AND THE GLOBALIZED PHARMACEUTICAL MANUFACTURING
Mercator, 2019
We approach the production of biomedicines in France as a productive spatial circuit. This circuit is part of the health-industrial complex (HIC), a concept that helps to explain the spatial and historical context to analyze the political economy of health care in France. Initially, we justify the use of the concept of the health-industrial complex, rather than the medical-industrial complex, as is commonly used in France and in Anglo-Saxon countries, and its relation to the political economy of health care. Then, we explain why the productive spatial circuit is more appropriate to a geographic approach of this industrial complex than the productive chain. Finally, we deal with the production of biomedicines and, more specifically, the importance of the Contract Development and Manufacturing Organization (CDMO) in the production of this technology to serve the major pharmaceutical laboratories, favoring the global production of this industrial branch.
Harvard Business School General Management Unit Working Paper No. 22-075,, 2022
This working paper investigates unintended consequences of U.S. FDI in Switzerland in the 1950s-1960s: the increased competition that U.S. firms generated within the national labor market and the challenge their hiring practices constituted for the institutional settings in which labor relations were embedded. It therefore contributes to two bodies of literature: one that deals with the arrival of U.S. firms in Europe after 1945 and another that tackles the contribution of business history to the variety of capitalism (VOC) scholarship.
Small state, big companies Rules for economic globalization and the role of Switzerland
2020
Switzerland is small, rich, and profits greatly from globalization. Consequently, it is under growing international and public pressure from those who wish to make the world economy "fairer" and "more sustainable" by means of transnational rules. Home to many multinational companies, Switzerland is highly exposed to any such regulatory changes. Yet it need not assume a passive role. Indeed, the very process of implementing rules for global companies provides valuable scope for action. This factsheet places the issue in a historical and legal context.
Swiss Pharmaceuticals and the Proximities with Regional Biotech Arenas
2014
The functions of research and develop-ment (R&D) are strategically among the most relevant sections of an enterprise in the pharmaceutical industry. At the same time, technology is a determining field for cooperation and competition among oligop-olistic rivals. Large companies, particularly in the pharmaceutical industry, invest enor-mous sums on research. International local-ization of R&D and its interweaving occur in an extremely selective spatial manner; that is, highly innovative and technologically advanced pharmaceutical R&D takes place in only a few countries and regions of the world. This fact raises the question of the importance of regional and local economic and social contexts for the organization of the R&D functions of large companies. The highly selective localization of multinational corporations ’ (MNCs’) research and tech-nology capacities, as well as the associated problems of scanning, production, transfer, and use of technological knowledge, are the focus of th...
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.